Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6895221 | 0.95 | FNTA (0.35) | FNTAPGGT1BGPR84GSTP1HCAR2 | |
| SCHEMBL1078427 | 0.89 | DAO (0.38) | FNTAPGGT1BGSTP1HCAR2DAO | |
| SCHEMBL31485230 | 0.83 | GSTP1 (0.42) | FNTAPGGT1BGPR84GSTP1GRIN2D | |
| SCHEMBL31436467 | 0.81 | FNTA (0.40) | FNTAPGGT1BGSTP1 | |
| SCHEMBL1150883 | 0.79 | ACHE (0.36) | GSTP1DAO | |
| SCHEMBL21633992 | 0.78 | GSTP1 (0.46) | GSTP1DAOSMN1; SMN2HTR2C | |
| SCHEMBL357488 | 0.77 | ACHE (0.43) | GPR84 | |
| SCHEMBL11105254 | 0.76 | LTB4R (0.40) | GSTP1 | |
| SCHEMBL6896832 | 0.76 | ACHE (0.46) | GPR84 | |
| SCHEMBL6898154 | 0.76 | ACHE (0.46) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833481-B2 | Catalytic dehydrative isomerization | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1316541-A1 | Process for producing 2-alkyl-2-cyclopentenones | Takasago International Corporation (JP) | 2003-06-04 | — | — | EP | disclosed |
| CN-1421429-A | Process for producing 2-alkyl-2-cyclopentenone | TAKASAGO PERFUMERY CO LTD (JP) | 2003-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | HSD3B2, DHPS, HSD3B1 | FNTA 2983/4885PGGT1B 1861/4885GPR84 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.